中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
页索引超出范围
Press Release
2023.03.31
Haihe Biopharma’s EZH1/2 inhibitor HH2853 completed first patient dosed in phase II part in China
2023.03.13
Haihe Biopharma's BET-BD2 Inhibitor HH3806 first patient dosed in Australia
2023.03.08
Haihe Biopharma Announces Gumarontinib Receives Approval from the NMPA of China for the Treatment of Locally Advanced or Metastatic NSCLC with MET Exon 14 Skipping Mutation
2022.12.03
Haihe Biopharma Presented latest studies of MET Inhibitor SCC244 in NSCLC at ESMO ASIA Congress 2022
2022.09.13
Haihe Biopharma Announces MAA Acceptance in China for Paclitaxel Oral Solution (RMX3001)
2022.04.12
Haihe Biopharma Presented Preliminary Clinical Data of MET Inhibitor Glumetinib (SCC244) in NSCLC at AACR Annual Meeting 2022
2022.03.09
China NMPA-CDE Grants Priority Review Designation to Haihe Biopharma’s Glumetinib (SCC244)
2022.02.18
Haihe Biopharma Announces NDA acceptance in China for MET inhibitor Glumetinib (SCC244)
2
3
4
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
